{"id":"NCT01346293","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age","officialTitle":"Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-04","primaryCompletion":"2013-05","completion":"2013-09","firstPosted":"2011-05-02","resultsPosted":"2015-05-29","lastUpdate":"2015-06-03"},"enrollment":3372,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Tetanus","Diphtheria","Pertussis","Measles","Polio"],"interventions":[{"type":"BIOLOGICAL","name":"Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus","otherNames":["DTap-IPV","M-M-R®II","VARIVAX®"]},{"type":"BIOLOGICAL","name":"Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus","otherNames":["DAPTACEL®","IPOL®","M-M-M R®II","VARIVAX®"]},{"type":"BIOLOGICAL","name":"Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus","otherNames":["DTap-IPV","M-M-R®II","VARIVAX®"]},{"type":"BIOLOGICAL","name":"Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus","otherNames":["DAPTACEL®","IPOL®","M-M-R®II","VARIVAX®"]}],"arms":[{"label":"Study Group 1","type":"EXPERIMENTAL"},{"label":"Study Group 2","type":"EXPERIMENTAL"},{"label":"Study Group 3","type":"EXPERIMENTAL"},{"label":"Study Group 4","type":"EXPERIMENTAL"}],"summary":"The study was designed to compare the safety and immunogenicity of DTap-IPV with DAPTACEL® + IPOL® as the 5th dose booster in children ≥ 4 to \\< 7 years of age in the US and Puerto Rico who were previously vaccinated with DAPTACEL® and/or Pentacel® vaccines only.\n\nPrimary Objectives:\n\n* To compare the pertussis \\[Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA), Pertactin (PRN), and Fimbriae Types 2 and 3 (FIM)\\] booster responses and geometric mean concentrations (GMCs) (as measured by enzyme-linked immunosorbent assay \\[ELISA\\]) following DTap-IPV vaccination to those elicited following DAPTACEL® + IPOL® vaccination when administered as a 5th dose.\n* To compare the diphtheria and tetanus booster responses and GMCs (as measured by ELISA) following DTap-IPV vaccination with those elicited following DAPTACEL® + IPOL® vaccinations when administered as a 5th dose .\n* To compare the Inactivated Poliovirus Vaccine booster responses (as measured by neutralizing assay) following DTap-IPV vaccination with those elicited following DAPTACEL® + IPOL® vaccinations.\n\nObservational Objectives:\n\n* To compare the polio (types 1, 2, and 3) geometric mean titers (GMTs) following DTap-IPV vaccination with those elicited following DAPTACEL® + IPOL® vaccinations.\n* To assess the safety of DTap-IPV vaccine or DAPTACEL® + IPOL® vaccine when administered as the fifth dose booster vaccine in participants previously vaccinated with DAPTACEL and/or Pentacel vaccines.","primaryOutcome":{"measure":"Number of Participants With Booster Response to the Pertussis Antigens Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine","timeFrame":"Day 0 (pre-vaccination) and Day 28 post-vaccination","effectByArm":[{"arm":"DTaP-IPV","deltaMin":240,"sd":null},{"arm":"DAPTACEL®+IPOL®","deltaMin":222,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":13},"locations":{"siteCount":72,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["27879555"],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":2733},"commonTop":["Injection site Pain","Change in limb circumference","Injection site Erythema","Myalgia","Injection site Swelling"]}}